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                                ABSTRACT 
 
Histone lysine and arginine residues are related to post-translational modifications 
including methylation, phosphorylation, acetylation, ubiquitination, and sumoylation. The 
combination these modifications regulates critical DNA processes including replication, 
repair, and transcription. The size and function of eukaryotic genomes require that 
specific mechanisms for the stability of DNA. Such mechanism is the comprise of DNA 
with histones to form chromatin which helps in gene expression. The most important 
thins is that histones impact transcriptional activity is through site-specific enzymatic 
modification of the amino terminal histone “tails”, which can alter the spectrum of 
chromatin-associated proteins and hence transcriptional states. Among the well known 
modifications of histones, lysine methylation is the best one to represent a relatively 
stable mark which might be suitable for stable activation or repression, depending upon 
the site modified., The activity of enzymes that modify histone lysine and arginine 
residues have been correlated with a variety of human diseases like arthritis, cancer, heart 
disease, diabetes, and neurological disorders. Thus, this is important to understand the 
total kinetic and chemical mechanisms of these enzymes. Many HMTs have been linked 
to different types of cancer; however, in many cases we only have limited knowledge 
regarding the molecular mechanisms by which the HMTs contribute to disease 
development. 
 
 
 
 
 
 
 INTRODUCTION: 
 Histones belong to a group of  evolutionarily conserved proteins which play an  
important role in the proper packaging of DNA in  the eukaryotic nucleus. DNA 
(~146 bp) together with histones (two each of histones H2A, H2B, H3 and H4) 
form the fundamental repeating subunit of chromatin & is known as   nucleosome.  
 It has been found that the human  genome is composed of approximately three 
billion bases of DNA (3,000,000,000 bp), so we can infer that there are tens of 
millions of nucleosomes within a single human nucleus.  
 Histones are in tight association with DNA, for which it has been postulated that 
they directly participate in many different DNA-templated programs including 
transcription, replication, recombination and DNA repair.  
 But there are some confusion over the role of histones, for example if each tiny 
histone protein contains the same exact amino acid sequence as the other millions 
of histones in nucleus, how could they possibly direct distinct and opposing 
nuclear processes? Widespread research is being carried on worldwide to find a 
probable answer to this question and it has been found that histone code may be a 
possible answer to the above mentioned question. 
 
      HISTONE METHYLTRANSFERASE 
 Histone methyltransferases (HMT) are group of enzymes consisting of histone-
lysine N-methyltransferase and histone-arginine N-methyltransferase that catalyze 
the process of transfer of one to three methyl groups from the cofactor S-
Adenosyl methionine to lysine and arginine residues of histone proteins. These 
protein is known to contain often a SET (Su(var)3-9, Enhancer of Zeste, 
Trithorax) domain. But  recenly it has been discovered that HMT Dot1 lacks the 
characteristic SET domain. 
 Histone methylation refers to the modification of certain amino acids in a histone 
protein by the addition of one, two, or three methyl groups. In the  nucleus,  DNA 
is wound around histones. Histones turns the genes in DNA "off" and "on", by 
methylation & demethylation respectively.  
  This modification changes the properties of the nucleosome and affects its 
interactions with other proteins . Histone methylation is generally associated with 
transcriptional repression. 
  Methylation of some lysine and arginine residues of histones causes 
transcriptional activation like methylation of lysine 4 of histone 3 (H3K4), and 
arginine (R) residues on H3 and H4. 
  Histones mainly  associates with DNA to form nucleosomes, which bundle to 
form chromatin fibers. They are globular proteins with a flexible N-terminus  that 
protrudes from the nucleosome. The tail modifications are important  
characteristics of  chromatin structure which  plays an important role in regulation 
of gene expression that is for details of gene expression regulation by histone 
modifications. 
 The nucleosome in eukaryotic organisms is the basic unit of chromosomes  which  
composed of a double-stranded DNA wrapped around a protein octamer 
consisting of two copies each of the histone proteins H2A, H2B, H3, and H4.  
 Histone proteins capable of various post-translational modifications including 
methylation, citrullination (deimination), acetylation, phosphorylation, 
ubiquitination, and simulations. 
 The combining effect of these modifications results in important DNA regulatory 
processes including replication, repair, and transcription. Within histone proteins, 
lysine and arginine residues are abundant and highly post-translationally 
modified. (Smith and Denu,2008) 
 Enzymes that modify these lysine and arginine residues have been correlated with 
ome of the human diseases such as rheumatoid arthritis, cancer, heart disease, 
diabetes and also with some neurodegenerative disorders such as Parkinson's 
disease and Alzheimer's disease. As a result of their involvement in a large variety 
of human disease states, it is highly important to understand the catalytic 
mechanisms of these enzymes. (Smith and Denu,2008) 
 
 Characterizing Histone Modification 
 Histones are modified at a wide variety of sites.  
 There are more than 60 different residues on histones where modifications have 
been detected  by specific antibodies or by mass spectrometry. 
 However, this represents lesser  number of modifications that can take place on 
histones.  
 Extra complexity arises partly from the fact that methylation at lysines or 
arginines may be one of three different forms: mono-, di-, or trimethyl for lysines 
and mono- or di- (asymmetric or symmetric) for arginines. 
 This vast number of modifications has a great  potential for functional responses, 
but it should be kept in the mind  that  all these modifications will not  be on the 
same histone at the  same time.  
 The timing of the appearance of a modification is uncertain & will depend on the 
signaling conditions within the cell.( Kouzaride Tonys,2007) 
 
Histone methyltransferases in cancer: 
  The human genome contains almost more than 20,000 genes, but among these genes 
are expressed in each of the nearly 200 cell types found in an adult organism. 
 Because of these differentiation of cells, certain genes are activated while others are 
repressed, which results in results in formation of a pattern of gene expression 
forming cellular identity.  
 This pattern of gene expression is directed by transcription factors, which bind to 
specific promoter and enhancer sequences. 
 Structure of chromatin plays an important role. Initially, chromatin was might be a 
static entity in which DNA is packaged to maintain the integrity of the molecule. 
Recently was found that the chromatin template undergoes dynamic changes during 
many cellular processes such as DNA replication and repair, recombination, cell 
cycle progression and transcription. 
  The current view is that evolution of cancer is driven by the sequential obtaining of  
both genomic and epigenomic changes, consequently resulting in activation of 
oncogenes and the suppressor of tumor-suppressor genes .  
 Epigenetic abnormalities in cancer comprise of many changes, including loss and 
gain of DNA methylation and alterations in histone methylation as well as 
acetylation. 
 In contrast to genetic lesions, epigenetic alterations are potentially reversible, 
allowing for therapeutic intervention. The field of epigenetic therapy is rapidly 
expanding and inhibitors targeting histone deacetylases (HDACs) and DNA methyl 
transferases (DNMTs) have been approved for treatment of certain blood cancers and 
are being tested in clinical trials for different types of cancer. (Albert and Helin,2009) 
        . 
Fig-1 Misregulation of tumor-suppressors and oncogenes by histone methyltransferases. 
Both genetic and epigenetic mechanisms are thought to contribute to cancer 
development. While tumor-suppressor genes might be inappropriately silenced by 
repressive histone modifications (A), histone methylation and acetylation marks 
associated with active transcription might promote the expression of oncogenes, 
(B).HMT:histone methyltransferase;HDM:histone demethylase; HAT: histone 
acetyltransferase; HDAC(Albert and Helin,2009) 
 
   REVIEW OF LITERAURE OF G9a 
 
  ROLE OF G9a IN EHCC (Extrahepatic Cholangiocarcinoma) (Chen et 
al.,2007). 
 Histone methyltransferase (HMTase) gene G9a composed of isonym protein i.e 
G9A, which transfers methyl groups from S-adenosyl-methionine to the lysine 
residues 9 and 27 of histone H3 (H3-K9 and H3-K27), methylation of  histone H3-
K9 is associated with the formation of chromatin, helps in gene expression, and 
regulation of DNA methylation in mammals . 
 Recent studies showed that it is an important epigenetic mechanism of human 
malignant tumor. To investigate roles of G9a in tumor genesis and progression, they 
(Chen et al.,2007) detected the expression of G9a at the process of mRNA and 
protein and observed its clinical significance in extrahepatic cholangiocarcinoma 
(EHCC). 
 As compared to other human histone methyltransferase such as SUV39H1 and 
ESET, it has been characterized to distinctive functions. Its first function is 
localization of G9a in nuclei suggested that this HMTase might target sites at 
transcriptionally active euchromatin rather than repressive percentric 
heterochromatin in which SUV39H1 family were localized . 
 The second function is that G9a stronger HMTase activity to H3-K9 as compared to 
SUV39H1, and never be compensated for any other methyltransferases . 
 The third function is that G9a transfers methyl groups to H3-K27 as well asH3-K9, 
whereas for SUV39H1 the targeting site was lonely Lys 9, recent study revealed 
that co-methylation of H3-K9 and H3-K27 is involved in gene silencing, specially 
for tumor suppressor gene. 
 These function mentioned above decided G9a plays a key role in the regulation of, 
development, cellular differentiation and cell-cycle progression. The disruption and 
genetic loss of G9a led to disorder of H3-K9 and H3-K27 methylation may be 
resulted in tumorigenesis.. (Chen et al.,2007). 
 
 Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome 
Disruption and Chromosome Instability in Cancer Cells. (Kondo et al., 2008) 
 Amino-terminal tails of Histone modifications  affect access of regulatory factors 
and complexes to chromatin and this influence biological processes. 
Characteristics of cancer cell are prominent epigenetic dysregulation, including 
histone modifications. However, the functional roles of the histone 
methyltransferases (HMT) in cancer still remain unclear. 
 Assembly of chromatin  regulate a critical process related to, gene expression,  
progression through the cell cycle and DNA  replicaton. 
 Some modifications are associated with certain DNA template mediated processes 
 One of the most well-studied histone modifications is methylation of histone H3 
lysine 9 (H3K9) .After the initial identification of SUV39h1 in addition to 
SUV39h2 as a H3K9-specific histone methyltransferase (HMT) at least three 
other G9a, ESET/SETDB1 and EuHMTase1, HMTs, have been recognized  for 
H3K9 in mammals . 
 These enzymes have many affinities for the un-, mono- or dimethylated states and 
produce many methylation states. Studies in knockout mice for Suv39h1, h2 
andG9a revealed that G9a is mainly responsible for (1Me) monomethylation and 
(2Me) dimethylation of H3K9, whereas Suv39h1 and Suv39h2 direct responsible  
for trimethylation (3Me) of H3K9. 
 Furthermore, monomethylation and dimethylation on H3K9 primarily occured in 
euchromatin, while dimethylation and trimethylation on H3K9 were found within 
different types of heterochromatin, mainly at facultative and constitutive 
heterochromatin. 
 The current study revealed that expression of SUV39H1 and G9a is important to 
enhance the growth of malignant cells and they play distinct roles in cancer cells.  
(Kondo et al., 2008) 
 
 
 
 Distinct Roles for Histone Methyltransferases G9a in Cancer Germ-Line 
Antigen Gene Regulation in Human Cancer Cells ( Petra et al., 2009). 
 Cancer germ-line (CG) antigens also called as cancer-testis antigens  are targets of 
tumor vaccines currently undergoing world wide evaluation of clinical processes.  
 Vaccine based on CG antigens in cancer includes both the inherent 
immunogenicity of these antigens and their restricted expression in normal human 
tissues as well as expression in human tumors .   
 Principally regulated CG antigen genes at the transcriptional level by epigenetic 
signals. 
 Lines of evidence are of following types: 
(a) Hypomethylation of promoter DNA correlates with CG antigen gene expression in 
human tumor  tissue and normal tissues . 
(b) Treatment of non-expressing cancer cells with epigenetic modulatory drugs, 
including DNA methyltransferase (DNMT) and histone deacetylase (HDAC) 
inhibitors, plays an important role in CG antigen gene expression. 
(c) Specific H3 modification patterns are associated with CG antigen gene expression 
level in human cancer cell. 
 To facilitate the clinical development of CG antigen-targeted therapeutic approaches 
more detailed elucidation of the epigenetic mechanisms regulating CG antigen gene 
expression in human cancer cells and tumors should Disruption of DNMT enzymes in 
human cancer cells results in reduced H3K9me2 levels at  CG antigen gene 
promoters,correlating with increased gene expression. . 
 These data suggested G9a may play a primary role in CG antigen gene repression in 
human cancer cells. ( Petra et al., 2009) 
 
 
 
  
 
 
 
    Hypoxic Stress Induces Dimethylated Histone H3 Lysine 9 through Histone             
   Methyltransferase G9a in Mammalian Cells. (chen et al 2006). 
 
 For chromatin organization and gene transcription an important mechanism are 
Post-translational modifications of histone amino-terminal tails, such as 
acetylation, methylation, ubiquitination, and phosphorylation, are important To 
date, histone acetylation and methylation are among the best-characterized 
modifications.  
 Histone lysine acetylations are generally comprised with gene activation, whereas 
lysine methylation may have either positive or negative effects such as activation 
or silencing on transcription depending on the sites. 
 Several H3K9-specific methyltransferases have been identified and characterized, 
as Suv39h1, Suv39h2, G9a, GLP EuHMTase1, and SETDB1/ESET. Among 
them, G9a and GLP EuHMTase1 are  responsible for the dimethylation processes 
on H3K9 in vivo. 
 The genetic alteration of either G9a or GLP/EuHMTase1 resulted in a loss of 
global H3K9me2 . G9a were found to be participated in gene silencing processes 
by interacting with many repressive transcriptional factors, such as, CDP/cut, 
PRDI-BF1/Blimp-1, NRSF/REST and SHP . 
 Hypoxia is commonly present in many solid tumors and always occure when the 
growth of tumors outstrips their blood supply. In case of  hypoxia, tumor cells 
increase the expression of genes related to angiogenesis, glucose and, glycolysis 
uptake using the transcription factor HIF . 
 Hypoxia may also decreases the expression of several genes, such as cellular 
DNA repair proteins and adhesion proteins  which leads to genetic instability and 
later which cause metastasis of tumor cells .  
 H3K9-specific methyltransferase G9a is identified as one of the important cause 
of the hypoxia-induced H3K9me2.  
 This conclusion is based on different lines of evidences, like hypoxia increased 
both G9a protein and HKMT activity as well as genetic alteration of G9a 
significantly induces the hypoxia-induced  H3K9me2.(chen et al 2006). 
                                      OBJECTIVE 
To check the expression of histone methyltranseferase in human cancer cell whether it is 
expressed or repressed. Our aim is to study the activity of G9a gene of histone 
methyltranseferase in human cancer. 
“Comparative Analysis of Histone Methyltransferase (HMTase) G9a Expression in 
Normal and various Human Cancer Tissues”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 MATERIALS AND METHODS 
The Human blood was collected from CWS Hospital, Rourkela as normal human tissue 
and Gall bladder and Lymph node cancer tissues were collected from Calcutta Medical 
College, Kolkata. 
a) Total RNA isolation 
            Reagents and Buffers:- 
 TRIzol Reagents (Sigma), 
 Choloroform, 
 Isopropanol, 
 Ethanol (70%), 
 Denaturation Buffer 
 50 % deionized formamide, 
 2.2 M formaldehyde, 
 MOPS buffer (pH 7.0), 
 6.6 % glycerol, 
 0.5 % bromphenol,  
 Ethidium Bromide (EtBr), 
 Agarose 
 
Protocol:- 
 50-100 mg of tissue in a 2 ml tube with 1 ml TRIzol was transferred. 
 Homogenized for 60 sec in the polytron. 
 200 l chloroform was added. 
 It was mixed by inverting the tube for 15 sec. 
 Incubated for 3 min at room temperature. 
 Centrifuged at 12.000 g for 15 min. 
 the aqueous phase was transferred into a fresh Eppendorf tube. 
 500 l isopropanol was added. 
 Centrifuged at max. 12.000 g for 10 min in the cold room. 
 The pellet was washed with 500 l 70 % ethanol. 
  Centrifuged at max. 7.500 g for 5 min in the cold room. 
 The pellet was dried on air for 10 min. 
 Then the pellet was dissolved in 50-100 l DEPC-H2O. 
 Incubated for 10 min at 60 C. 
 Spectrophotometric reading was taken. 
 Analysed the RNA on a MOPS gel: 
 1-3 g RNA was dissolved in 11 l denaturation buffer. 
 1 l Ethidium bromide (1mg/ml) was added and denatured at 65 C for 15 
min 
 1 % agarose gel was loaded in MOPS buffer plus 5 % formaldehyde. 
 The gel was run at 40 V for 4 h. 
 
b) cDNA synthesis (rt-PCR):  
Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNase OUT Ribonuclease Inhibitor 
 Super Script II RNase H- Reverse Transcriptase 
 
Protocol:- 
 8µl of total RNA were taken. 
 Then 3 μl Random Primers was added. 
 
 1 μl dNTP mix was added. 
 Then vortex and spin downed tube. 
 Incubated at 65°C for 5 min. 
 Placed tube on ice. 
 4 μl 5X Buffer, 2 μl DTT and 1μl RNAseOut were added. 
 Then vortex and spin downed tube. 
  Incubated at 42°C for 1 min. 
 1μl SuperScript II RNase H- Reverse Transcriptase was added. 
 Incubated at 42°C for 60 min. 
 Incubated at 70°C for 15 min. 
 180 μl of molecular grade water was added. 
 Nano drop 1000 was used to measure concentration. Set sample typesetting to 
Other Sample and the constant to 33. 
 Stored at -80°C. 
 
c) Gene specific PCR: 
Used Primers:- 
Gene Forward Primer Reverse Primer 
 
G9a 
 
 
 
5’ATGGTGTGGGCTCCTCA-3’ 
 
 
5’TGAAGCTCAAGAGGTGA-3’ 
 
 
β actine 
 
 
 TCTACAATGAGCTGCGTGTG 
 
  
TCCTGTCATCTCCTTCTGC 
                      
                                                                                                    Chen et al (2007) 
 
 
 
 
 
 
 d) PCR mixture:- (Chen et al., 2007): 
 25 ml reaction volume 
A typical reaction contained: template RNA 0.5 μg, up  
down-stream primer 0.3 μL each,  
10 × buffer 2.5 μL,  
Mg2+(25 mol/L) 1.5 μL,  
dNTP (2.5 mol/L) 2 μL,  
Taq (5U/μL,Promega) 0.25 μL and  
DEPC water 16.15 Μl 
. 
 
e) PCR conditions:-  (Chen et al., 2007): 
PCR reactions were performed in a PTC-200 thermal cycler (MJ Research, Watertown, 
MA)  
95 ℃ for 2 min,  
95℃   for 1 min,  
58 ℃ for 1 min, and  
72℃  for 1 min, 
 34 cycles,  
then 72℃  for 4 min. 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS  
 
 
RNA Extraction From Normal Tissue (Blood): 
 
Product Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Total RNA 570.32 1.34 0.82 
Table.1: Spectrophotometer results of total RNA from blood tissue 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Total RNA in 1% agarose gel] 
[Total RNA in denaturation gel] 
 RNA Extraction From Cancerous Tissue: 
Tissue Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
Gall Bladder Cancer 234.67 1.03 0.65 
Lymph Node Cancer 478.51 1.61 1.02 
Table.2: Spectrophotometer results of total RNA from cancerous tissue 
          
                                                    Lane.1: Lymph Node Cancer 
                                                            Lane.2: Gall Bladder Cancer         
 
 
 
Expression of G9a in Normal Blood: 
Gene Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
G9a 280.69 1.50 0.76S 
Table.3: Spectrophotometer results of gene specific amplification product from blood 
                                                 
                                                        
1          2 
[Total RNA in 
denaturation gel] 
                      G9a 
[Gene specific PCR amplification] 
 
 Expression of G9a in Lymph Node Cancer                                      
                                                        
Gene Conc
n
.
 
(µg/ml) Purity 
260/280 260/230 
G9a 1820 0.98 1.27 
Table.5: Spectrophotometer results of gene specific amplification product from lymph 
node cancer tissue  
 
                                                                                                                                                                                                          
      1     2      3      4     5     6     7    8                                    
                                 
              [Gene specific PCR amplification] 
 
 
 
                                          
LANE 1:B actine 
                                                                                                              
LANE 3:GADD45 
                                                                                                              
LANE 4:G9a 
                                                                                                            
LANE 7:DNA Ladder       
                                         DISCUSSION 
 
After isolation the total RNA from normal blood and Cancerous tissue, we checked their 
concentration by taking its OD in spectrophotometer, in case of Gall Bladder the 
concentration was found to be very low i.e. 234.67µg/ml, which was very low compare to 
the other samples reading. Because it took a lot of time to processing after collecting the 
sample and also cDNA was not synthesize from the total RNA by rt-PCR method. 
 
In case of lymph Node Cancer G9a is not expressed. This may be due to over production 
of other histone metyltransferases (for example, EZH2). Because of over expression of 
p300 lymph node cancer genome may be under the threat of drastic histone acetylation. 
Over expression of p300 may suppress H3K9 Methylation. EZH2 is overexpressed in 
case of lymph node cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
                                       CONCLUSION 
 
Studies of histone modifications and related molecular biology have entered an exciting 
phase, in which it has become possible to directly test the contribution of particular 
histone modifications to cellular and organism physiology.  
Expression of G9a is present in many Cancer like Lung cancer, extrahepatic 
cholangiocarcinoma etc. But we find that repression of G9a in Lymph Node Cancer 
tissues.  
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